In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.

Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning / Massari, Francesco; Rosellini, Matteo; Mollica, Veronica. - In: NATURE REVIEWS. UROLOGY. - ISSN 1759-4812. - ELETTRONICO. - 1:(2024), pp. 1-2. [10.1038/s41585-024-00896-6]

Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning

Massari, Francesco
Primo
;
Rosellini, Matteo;
2024

Abstract

In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.
2024
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning / Massari, Francesco; Rosellini, Matteo; Mollica, Veronica. - In: NATURE REVIEWS. UROLOGY. - ISSN 1759-4812. - ELETTRONICO. - 1:(2024), pp. 1-2. [10.1038/s41585-024-00896-6]
Massari, Francesco; Rosellini, Matteo; Mollica, Veronica
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/969836
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact